AtriCure Inc. (OQ:ATRC)

Business Focus: Medical Equipment, Supplies & Distribution

Jul 07, 2020 08:00 am ET
AtriCure to Announce Second Quarter 2020 Financial Results
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments f
May 11, 2020 08:10 pm ET
AtriCure Announces Pricing of Public Offering of Common Stock
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in tre
May 11, 2020 07:16 am ET
AtriCure Announces Proposed Public Offering of Common Stock
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in tre
May 08, 2020 08:47 am ET
AtriCure Announces Results from CONVERGE IDE Clinical Trial
“The CONVERGE study is a monumental step forward in the market focused on the most difficult to treat Afib patients, those with persistent or long-standing persistent forms of the disease,” said Michael Carrel, President and Chief Executive Officer at AtriCure. “This patient population represents many millions of patients and more than two-thirds of all diagnosed Afib patients. The study results presented at HRS mark a major milestone for the CONVERGE study and we look forward to working with the FDA moving forward.”
Apr 30, 2020 08:30 am ET
Apr 29, 2020 04:01 pm ET
Apr 27, 2020 04:02 pm ET
AtriCure to Participate at Upcoming Investor Conferences
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical tre
Apr 15, 2020 08:00 am ET
AtriCure to Announce First Quarter 2020 Financial Results
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments f
Apr 13, 2020 08:00 am ET
Apr 09, 2020 08:00 am ET
Feb 18, 2020 04:01 pm ET
AtriCure Reports Fourth Quarter 2019 and Full Year 2019 Financial Results
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial
Feb 03, 2020 08:00 am ET
AtriCure to Participate at the SVB Leerink 9th Annual Global Healthcare Conference
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical tre
Jan 28, 2020 08:00 am ET
AtriCure to Announce Fourth Quarter and Full Year 2019 Financial Results
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments f
Jan 13, 2020 08:00 am ET
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2019, Provides Financial Outlook for 2020
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced preliminary financial results for the fourth quarter and full year 2019 and provided 2020 financial guidance.
Jan 07, 2020 08:00 am ET
AtriCure Announces Successful Completion of Patient Enrollment of aMAZE Clinical Trial and FDA Approval of Continued Access Protocol
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced the successful completion of patient enrollment in the aMAZE™ clinical trial. In addition, the company announced that it has received approval from the Food and Drug Administration (FDA) for the continuation of the trial under a Continued Access Protocol (CAP) with an additional patient enrollment of up to 85 patients and the opportunity to further expand to 250 patients while the pre-market
Dec 16, 2019 08:00 am ET
AtriCure to Participate at the 38th Annual JP Morgan Healthcare Conference
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical tre
Dec 04, 2019 08:00 am ET
AtriCure Names Two Industry Veterans to Board of Directors
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial append
Nov 12, 2019 08:00 am ET
AtriCure to Participate at the Piper Jaffray 31st Annual Healthcare Conference
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillatio
Oct 30, 2019 04:02 pm ET
AtriCure Reports Third Quarter 2019 Financial Results
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) managem
Oct 21, 2019 08:00 am ET
AtriCure to Participate in Upcoming Investor Conferences
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillatio
Oct 08, 2019 08:00 am ET
AtriCure to Announce Third Quarter 2019 Financial Results
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib)
Aug 27, 2019 08:00 am ET
AtriCure Receives Clearance for Expanded Labeling Claims for AtriClip Devices
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatment for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance of additional labeling claims for AtriClip® LAA management devices, including changing the indication from occlusion of the LAA to exclusion, and also adding electrical isolation as a labeling claim. Exclusion shuts off and/or eliminates the appendage from the left atrium, whereas occlusion plugs the opening to prevent flow into the LAA. The ele
Aug 26, 2019 08:00 am ET
AtriCure to Participate at the Morgan Stanley 17th Annual Global Healthcare Conference
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatme
Aug 13, 2019 02:16 pm ET
AtriCure Completes Acquisition of SentreHEART
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it has completed its previously announced acquisition of SentreHEART, Inc., a privately held developer of percutaneous left atrial appendage management solutions.
Aug 12, 2019 05:30 am ET
AtriCure Enters Into Definitive Agreement to Acquire SentreHEART
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it has entered into a definitive agreement to acquire SentreHEART, Inc., a privately held developer of percutaneous left atrial appendage management solutions. The company also announced updated full year 2019 guidance.
Jul 30, 2019 04:02 pm ET
AtriCure Reports Second Quarter 2019 Financial Results
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrill
Jul 17, 2019 04:00 pm ET
AtriCure to Participate at the Canaccord Genuity 39th Annual Growth Conference
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillatio
Jul 10, 2019 08:00 am ET
AtriCure to Announce Second Quarter 2019 Financial Results
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib)
Apr 25, 2019 04:01 pm ET
AtriCure Reports First Quarter 2019 Financial Results
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial
Apr 23, 2019 08:00 am ET
AtriCure Announces First Patient Enrollment in the DEEP IDE Trial Restart
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatment for atrial fibrillation (Afib) and left atrial appendage management, today announced the restart of the Dual Epicardial and Endocardial Procedure (DEEP) clinical trial (NCT02393885). Following approval by the FDA to restart the trial and enroll an additional 40 subjects, which was granted in December 2018, the first patient was treated by a team led by Professor Mark La Meir and Professor Carlo de Asmundis at Universitair Ziekenhuis Brussels, Belgium.
Apr 04, 2019 08:00 am ET
AtriCure to Announce First Quarter 2019 Financial Results
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fi
Apr 01, 2019 10:00 am ET
AtriCure to Present at the Needham & Company’s 18th Annual Healthcare Conference
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for
Mar 05, 2019 07:40 am ET
Factors of Influence in 2019, Key Indicators and Opportunity within Expedia Group, Lumentum, Patterson Companies, Allscripts Healthcare Solutions, AtriCure, and Biohaven Pharmaceutical Holding — New R
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Expedia Group, Inc. (NASDAQ:EXPE), Lumentum Holdings Inc....
Feb 28, 2019 04:02 pm ET
AtriCure Reports Fourth Quarter and Full Year 2018 Financial Results
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fi
Feb 19, 2019 08:00 am ET
AtriCure Announces The Society of Thoracic Surgeons Has Endorsed the Company’s Advanced Ablation Courses in the United States
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatment for atrial fibrillation (Afib) and left atrial appendage management, today announced that The Society of Thoracic Surgeons (STS) has endorsed its Advanced Ablation course for both physicians and fellows. The course provides surgeons and other medical professionals with a comprehensive overview of the treatment of Afib during cardiac surgery.
Feb 12, 2019 08:00 am ET
AtriCure Announces Launch of the cryoICE® cryoSPHERE™ Probe
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management (LAAM), today announced that it has launched the cryoICE® cryoSPHERE™ probe in the United States. The cryoSPHERE probe is the first device in the cryoICE family solely dedicated to blocking pain by temporarily ablating peripheral nerves.
Feb 05, 2019 08:00 am ET
AtriCure Announces the First Patient Enrolled in the ICE-AFIB™ Clinical Trial
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatment for atrial fibrillation (Afib) and left atrial appendage management, today announced the first patient was treated in the ICE-AFIB™ trial (NCT03732794). Following Investigational Device Exemption (IDE) approval by the FDA, the first patient was treated by Dr. Niv Ad, at Washington Adventist Hospital in Takoma Park, Maryland. The trial will evaluate the safety and effectiveness of the cryoICE Ablation System for the treatment of persistent and long-standing persistent atrial
Feb 04, 2019 08:30 am ET
AtriCure to Announce Fourth Quarter and Full Year 2018 Financial Results
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fi
Jan 28, 2019 07:25 am ET
Recent Analysis Shows Textron, Occidental Petroleum, AtriCure, Chegg, KBR, and V.F. Market Influences — Renewed Outlook, Key Drivers of Growth
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Textron Inc. (NYSE:TXT), Occidental Petroleum Corporation (NYSE:OXY),...
Jan 07, 2019 08:30 am ET
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2018
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced preliminary financial results for the fourth quarter and full year 2018 and provided 2019 financial guidance.
Dec 13, 2018 08:00 am ET
AtriCure to Present at the 37th Annual J.P. Morgan Healthcare Conference
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for
Nov 12, 2018 08:40 am ET
Detailed Research: Economic Perspectives on Roku, Exelixis, Scientific Games, Boot Barn, Astronics, and AtriCure — What Drives Growth in Today's Competitive Landscape
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Roku, Inc. (NASDAQ:ROKU), Exelixis, Inc. (NASDAQ:EXEL), Scientific...
Nov 08, 2018 09:30 am ET
AtriCure to Present at the Piper Jaffray 30th Annual Healthcare Conference
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for at
Nov 01, 2018 04:01 pm ET
AtriCure Reports Third Quarter 2018 Financial Results
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibr
Oct 22, 2018 04:01 pm ET
AtriCure to Participate in Upcoming Investor Conferences
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for at
Oct 12, 2018 09:10 am ET
Report: Developing Opportunities within Agree Realty, Lattice Semiconductor, American Outdoor Brands, Schneider National, AtriCure, and Universal Display — Future Expectations, Projections Moving into
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Agree Realty Corporation (NYSE:ADC), Lattice Semiconductor Corporation...
Oct 11, 2018 08:00 am ET
AtriCure to Announce Third Quarter 2018 Financial Results
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibr
Oct 04, 2018 06:09 pm ET
AtriCure Announces Pricing of Public Offering of Common Stock
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced the pricing of its underwritten offering of 2.5 million shares of its common stock at a price to the public of $30.75 per share pursuant to its existing shelf registration statement. Net proceeds to AtriCure from the offering are expected to be approximately $72 million, after deducting underwriting discounts and commissions and estimated offering expenses. AtriCure has granted to the underwr
Oct 03, 2018 04:01 pm ET
AtriCure Announces Proposed Public Offering of Common Stock
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced it has commenced an underwritten public offering of 2.5 million shares of its common stock pursuant to its existing shelf registration statement. In connection with this offering, AtriCure plans to grant the underwriters of the offering a 30-day option to purchase up to 375,000 additional shares of common stock at the public offering price less the underwriting discount. AtriCure intends to u
Oct 03, 2018 04:01 pm ET
AtriCure Reports Preliminary Financial Results for Third Quarter 2018
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibr
Aug 28, 2018 08:00 am ET
AtriCure Announces Completion of Patient Enrollment in the CONVERGE IDE Clinical Trial
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has completed enrollment of the full cohort of 153 patients in the CONVERGE IDE clinical trial.
Aug 21, 2018 08:00 am ET
AtriCure to Present at the Morgan Stanley Global Healthcare Conference
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibr
Aug 08, 2018 08:25 am ET
Report: Exploring Fundamental Drivers Behind BancFirst, Materion, Acuity Brands, USA Truck, Marriott International, and AtriCure — New Horizons, Emerging Trends, and Upcoming Developments
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of BancFirst Corporation (NASDAQ:BANF), Materion Corporation (NYSE:MTRN),...
Aug 01, 2018 04:01 pm ET
AtriCure Reports Second Quarter 2018 Financial Results
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibr
Jul 24, 2018 04:30 pm ET
ViewRay Appoints Scott Drake as President, Chief Executive Officer and a Member of the Board of Directors, Shar Matin as Chief Operating Officer, and D. Keith Grossman as a Member of the Board of Dire
CLEVELAND, July 24, 2018 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY), maker of the market-leading MRI-guided radiation therapy system, announced today the appointment of medical device industry veterans Scott Drake as its President and Chief Executive Officer and Shar Matin as its Chief Operating Officer, effective immediately.  In connection with his appointment, Mr. Drake has also been appointed to the ViewRay Board of Directors.  In addition, ViewRay announced the appointment of D. Keith Grossman to the ViewRay Board of Directors....
Jul 16, 2018 08:00 am ET
AtriCure to Present at the Canaccord Genuity 38th Annual Growth Conference
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for at
Jul 11, 2018 08:00 am ET
AtriCure to Announce Second Quarter 2018 Financial Results
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibr
Jun 12, 2018 08:00 am ET
AtriCure Announces 2018 Analyst and Investor Meeting
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibr
Jun 05, 2018 06:00 am ET
AtriCure and Baheal Group Establish Partnership and China Distribution Agreement
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has partnered with Baheal Pharmaceutical Group in China to distribute AtriCure’s surgical ablation devices. This new multi-year agreement establishes Baheal as the exclusive distributor for AtriCure, and replaces the company’s previous distributor in China.
Apr 26, 2018 04:05 pm ET
AtriCure Reports First Quarter 2018 Financial Results
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibr
Apr 05, 2018 08:00 am ET
AtriCure to Announce First Quarter 2018 Financial Results
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibr
Mar 15, 2018 08:00 am ET
AtriCure to Present at the Needham & Company’s 17th Annual Healthcare Conference
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for at
Mar 02, 2018 07:40 am ET
Report: Developing Opportunities within LCI Industries, Biglari, Graco, Federal Signal, AtriCure, and Perry Ellis International — Future Expectations, Projections Moving into 2018
NEW YORK, March 02, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of LCI Industries (NYSE:LCII), Biglari Holdings Inc....
Feb 26, 2018 04:05 pm ET
AtriCure Reports Fourth Quarter and Full Year 2017 Financial Results
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibr
Feb 26, 2018 12:00 pm ET
AtriCure, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 26, 2018 / AtriCure, Inc. (NASDAQ: ATRC) will be discussing their earnings results in their Q4 Earnings Call to be held on February 26, 2018 at 4:30 PM Eastern Time.
Feb 22, 2018 08:00 am ET
AtriCure Launches the AtriClip® FLEX•V™ Device in the United States
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibr
Feb 20, 2018 08:00 am ET
AtriCure Names Scott Drake Board Chairman
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for at
Feb 07, 2018 08:00 am ET
AtriCure to Announce Fourth Quarter and Full Year 2017 Financial Results
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibr
Jan 08, 2018 08:00 am ET
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2017
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibr
Jan 08, 2018 07:35 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within Insys Therapeutics, LGI Homes, Steelcase, AtriCure, Alliance Holdings GP, and Digital Turbine — New Research Emphasizes Economic Gro
NEW YORK, Jan. 08, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Insys Therapeutics, Inc. (NASDAQ:INSY), LGI Homes,...
Dec 14, 2017 04:05 pm ET
AtriCure to Present at the 36th Annual JP Morgan Healthcare Conference
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for at
Nov 09, 2017 04:05 pm ET
AtriCure to Present at the Piper Jaffray 29th Annual Healthcare Conference
AtriCure, Inc. (Nasdaq:ATRC), a leading innovator in surgical treatments for atri
Nov 01, 2017 04:05 pm ET
AtriCure Reports Third Quarter 2017 Financial Results
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibr
Oct 20, 2017 08:00 am ET
AtriCure to Present at the Stifel Healthcare Conference
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for at
Oct 11, 2017 11:11 am ET
Mike Hooven, Founder of AtriCure (NASDAQ: ATRC) and Enable Injections, Joins Genetesis Board of Directors
Genetesis, a medical technology company that gives doctors an accurate, non-invasive tool for seeing how the heart beats, announces the addition of Mike Hooven to its Board of Directors.
Oct 10, 2017 08:00 am ET
AtriCure to Announce Third Quarter 2017 Financial Results
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibr